A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

  • STATUS
    Recruiting
  • days left to enroll
    75
  • participants needed
    22
  • sponsor
    National Cancer Institute (NCI)
Updated on 26 January 2021
cardiovascular disease
ct scan
platelet count
cancer
hypertension
amylase
antiretroviral
heart failure
systemic therapy
measurable disease
carcinoma
vegf
lipase
growth factor
kinase inhibitor
major surgery
metastasis
progressive disease
neutrophil count
brain metastases
vascular endothelial growth factor
kidney tumor
kidney cancer
renal neoplasm

Summary

Background
  • Papillary RCC is the second most common histologic subtype of kidney cancer, accounting for approximately 10-15% of cases
  • Type 1 papillary RCC occurs in both sporadic and hereditary forms, which are histologically identical. Non familial type 1 papillary RCC can present as both solitary renal tumors and as bilateral, multifocal disease
  • There are no standard agents of proven efficacy for patients with advanced papillary

RCC.

  • Patients with disease localized to the kidney are managed surgically while patients with advanced/unresectable disease are usually managed in the community with VEGF pathway antagonists or mTOR inhibitors.
  • Activating mutations of MET were identified in the germline of affected HPRC patients, who have a predilection for the development of bilateral, multifocal type 1 papillary RCC. Somatic MET mutations have been found in a subset of patients with non-inherited, sporadic papillary renal carcinoma
  • The investigational agent INC280 is a selective MET inhibitor lacking activity against the VEGF pathway
  • This is a proof-of-concept study using INC280 in patients with papillary RCC to test the idea that effectively blocking the HGF/MET pathway will lead to clinical activity in patients with papillary renal cell cancer
    Objectives

Primary Objective:

-To determine the overall response rate (RECIST 1.1) in patients with papillary renal cell carcinoma treated with single agent INC280

Eligibility
  • Diagnosis of hereditary papillary renal carcinoma (HPRC) or sporadic papillary renal cell carcinoma (RCC)
  • Patients with bilateral multifocal disease can have tumors localized to the kidney or have metastatic disease
  • Patients with sporadic papillary RCC (but without multifocal disease) should have advanced disease that is considered unresectable
  • ECOG 0-2
  • Measurable disease
  • Adequate organ function
  • No active brain metastases
  • Prior therapy
  • No more than 3 prior lines of systemic therapy
  • Prior therapy with a MET inhibitor is allowed as long as the patient has not had progressive disease while receiving the agent
Design
  • This is a phase 2 single center non-randomized trial.
  • The study will be conducted using a Simon 2 stage minimax design. Initially 13 evaluable subjects will be recruited. If there are no responses to therapy, the study will be terminated. If there is at least 1 response an additional 7 evaluable subjects will be accrued.
  • The two-stage minimax design is based on assuming an ineffective response rate of 5% and a targeted effective response rate of 25%. We also assume that the probability of accepting an ineffective treatment and the probability of rejecting an effective treatment are each 10%.
  • Subjects will be dosed orally at a starting dose of 600 mg twice daily.
  • The overall response rate (complete response + partial response) will be determined.

Description

Background
  • Papillary RCC is the second most common histologic subtype of kidney cancer, accounting for approximately 10-15% of cases
  • Type 1 papillary RCC occurs in both sporadic and hereditary forms, which are histologically identical. Non familial type 1 papillary RCC can present as both solitary renal tumors and as bilateral, multifocal disease
  • There are no standard agents of proven efficacy for patients with advanced papillary

RCC.

  • Patients with disease localized to the kidney are managed surgically while patients with advanced/unresectable disease are usually managed in the community with VEGF pathway antagonists or mTOR inhibitors.
  • Activating mutations of MET were identified in the germline of affected HPRC patients, who have a predilection for the development of bilateral, multifocal type 1 papillary RCC. Somatic MET mutations have been found in a subset of patients with non-inherited, sporadic papillary renal carcinoma
  • The investigational agent INC280 is a selective MET inhibitor lacking activity against the VEGF pathway
  • This is a proof-of-concept study using INC280 in patients with papillary RCC to test the idea that effectively blocking the HGF/MET pathway will lead to clinical activity in patients with papillary renal cell cancer
    Objectives

Primary Objective:

-To determine the overall response rate (RECIST 1.1) in patients with papillary renal cell carcinoma treated with single agent INC280

Eligibility
  • Diagnosis of hereditary papillary renal carcinoma (HPRC) or sporadic papillary renal cell carcinoma (RCC)
  • Patients with bilateral multifocal disease can have tumors localized to the kidney or have metastatic disease
  • Patients with sporadic papillary RCC (but without multifocal disease) should have advanced disease that is considered unresectable
  • ECOG 0-2
  • Measurable disease
  • Adequate organ function
  • No active brain metastases
  • Prior therapy
  • No more than 3 prior lines of systemic therapy
  • Prior therapy with a MET inhibitor is allowed as long as the patient has not had progressive disease while receiving the agent
Design
  • This is a phase 2 single center non-randomized trial.
  • The study will be conducted using a Simon 2 stage minimax design. Initially 13 evaluable subjects will be recruited. If there are no responses to therapy, the study will be terminated. If there is at least 1 response an additional 7 evaluable subjects will be accrued.
  • The two-stage minimax design is based on assuming an ineffective response rate of 5% and a targeted effective response rate of 25%. We also assume that the probability of accepting an ineffective treatment and the probability of rejecting an effective treatment are each 10%.
  • Subjects will be dosed orally at a starting dose of 400 mg twice daily.
  • The overall response rate (complete response + partial response) will be determined.

Details
Condition urinary tract neoplasm, Malignant neoplasm of kidney, Nephropathy, Renal Cell Carcinoma, Kidney Disease (Pediatric), Kidney Cancer, Kidney Disease, Renal Cell Cancer, Renal Cancer, Urologic Cancer, cancer, renal
Treatment INC280
Clinical Study IdentifierNCT02019693
SponsorNational Cancer Institute (NCI)
Last Modified on26 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Renal Cell Cancer or Kidney Cancer or Malignant neoplasm of kidney or Kidney Disease or urinary tract neoplasm or Renal Cancer or Urologic Cancer or K...?
Do you have any of these conditions: Kidney Disease or Kidney Disease (Pediatric) or Malignant neoplasm of kidney or urinary tract neoplasm or Urologic Cancer or Kidney Cancer or Renal Ce...?
Do you have any of these conditions: Kidney Disease (Pediatric) or Kidney Cancer or urinary tract neoplasm or Malignant neoplasm of kidney or Nephropathy or Renal Cell Cancer or Kidney Di...?
Do you have any of these conditions: Kidney Cancer or Urologic Cancer or Kidney Disease or Nephropathy or Renal Cell Cancer or cancer, renal or Malignant neoplasm of kidney or Renal Cance...?
Do you have any of these conditions: Kidney Cancer or Kidney Disease (Pediatric) or Urologic Cancer or Renal Cancer or Nephropathy or Renal Cell Cancer or Malignant neoplasm of kidney or ...?
[2.1.1.1](telnet://2.1.1.1) Patients must have histologically or cytologically
confirmed papillary RCC
Patients with bilateral multifocal disease can have tumors localized to the kidney or have metastatic disease
Patients with sporadic papillary RCC (but without multifocal disease) should have advanced disease that is considered unresectable
[2.1.1.2](telnet://2.1.1.2) Patients must have measurable disease, defined as
at least one lesion that can be accurately measured in at least one dimension
(longest diameter to be recorded for nonnodal lesions and short axis for nodal
lesions). Nodal lesions must be (Bullet) 15mm by CT scan or MRI. Non nodal
lesions must be >10 mm with CT scan or MRI
[2.1.1.3](telnet://2.1.1.3) Patients must have normal organ and marrow
function as defined below
Hemoglobin > 9 g/dL (SI Units: 90 g/L)
Platelet count greater than or equal to 75 x 10 (9)/L
Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10(9)/L without growth factor support
Total bilirubin less than or equal to 2 x upper limit of normal (ULN)
AST/SGOT and/or ALT/SGPT less than or equal to 2.5 x upper limit of normal (ULN)
Serum creatinine less than or equal to 1.5 x ULN
Asymptomatic serum amylase less than or equal to 2 x ULN; patients with > ULN but less than or equal to 2 x ULN serum amylase at study start must be confirmed to have no signs and/or symptoms suggestion pancreatitis or pancreatic injury ( e.g. elevated P-amylase, abnormal imaging findings of pancreas, etc.)
Serum lipase less than or equal to ULN
Fasting serum triglyceride level less than or equal to 500 mg/dL
[2.1.1.4](telnet://2.1.1.4) Patients may have had no more than 3 prior lines
of systemic therapy. Prior therapy with a MET inhibitor is allowed as long as
the patient has not had progressive disease while receiving the agent
[2.1.1.5](telnet://2.1.1.5) Patient must be able to swallow and retain oral
medication
[2.1.1.6](telnet://2.1.1.6) Age greater than or equal to18 years
[2.1.1.7](telnet://2.1.1.7) ECOG performance status 0 - 2
[2.1.1.8](telnet://2.1.1.8) Patients must provide written informed consent
prior to any study procedures
[2.1.1.9](telnet://2.1.1.9) Patients must be willing and able to comply with
scheduled visits, treatment plan and laboratory tests
EXCLUSION CRITERIA
[2.1.2.1](telnet://2.1.2.1) Patients who are receiving any other
investigational agents for treatment of their kidney cancer
[2.1.2.2](telnet://2.1.2.2) History of allergic reactions attributed to
compounds of similar chemical or biologic composition to INC280. Excipients in
the current formulation include microcrystalline cellulose, mannitol, sodium
starch glycolate, magnesium stearate and colloidal silicon dioxide
[2.1.2.3](telnet://2.1.2.3) Uncontrolled intercurrent illness including, but
not limited to, ongoing or active infection requiring intravenous antibiotics
symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit
compliance with study requirements or potentially affect the interpretation of
study data
[2.1.2.4](telnet://2.1.2.4) Subjects with significant or uncontrolled
cardiovascular disease (e.g., uncontrolled hypertension, peripheral vascular
disease, congestive heart failure, cardiac arrhythmia, or acute coronary
syndrome) within 6 months prior to starting study treatment or heart attack
within 12 months prior to starting study treatment
[2.1.2.5](telnet://2.1.2.5) Patients receiving any medications that are known
to be strong inducers or inhibitors of CYP3A4, or sensitive substrates of
CYP3A4, CYP1A2, CYP2C9, CYP2C9, CYP2C19 or P-gp with a narrow therapeutic
index
[2.1.2.6](telnet://2.1.2.6) Symptomatic CNS metastases that are neurologically
unstable or requiring > 5 mg/day of dexamethasone (or equivalent) to control
CNS disease
Note: Patients with controlled CNS metastases are allowed. Radiotherapy or
surgery for CNS metastases must have been completed >2 weeks prior to study
entry. Patients must be neurologically stable, having no new neurologic
deficits on clinical examination, and no new findings on CNS imaging. Steroid
use for management of CNS metastases must be at a stable dose for two weeks
preceding study entry
[2.1.2.7](telnet://2.1.2.7) Patients with greater than or equal to Grade 2
neuropathy
[2.1.2.8](telnet://2.1.2.8) Treatment with proton pump inhibitors within 3
days prior to study entry. If continued use of GI prophylaxis is required, the
patient will be switched to an appropriate H2 antagonist with appropriate
counsel and caution
[2.1.2.9](telnet://2.1.2.9) Currently receiving any prohibited medications
including vitamins and herbal Supplements
[2.1.2.10](telnet://2.1.2.10) Major surgery within 4 weeks prior to initiating
treatment, excluding the placement of vascular access
[2.1.2.11](telnet://2.1.2.11) The subject has not recovered to baseline, CTCAE
less than or equal to Grade 1 from toxicity due to all prior therapies for RCC
or to a level permitted under other sections of the eligibility criteria
except alopecia and other non-clinically significant AEs
[2.1.2.12](telnet://2.1.2.12) Any other condition that would, in the
Investigator s judgment, contraindicate participation in the clinical study
due to safety concerns or compliance with clinical study procedures, e.g
infection/inflammation, intestinal obstruction, unable to swallow medication
social/ psychological issues, etc
[2.1.2.13](telnet://2.1.2.13) Pregnant or nursing (lactating) women, where
pregnancy is defined as the state of a female after conception and until the
termination of gestation, confirmed by a positive hCG laboratory test (> 30
mIU/mL). Laboratory values >5 mIU/mL, but <30 mIU/mL should be repeated in 48
hours
[2.1.2.14](telnet://2.1.2.14) Women of child-bearing potential, defined as all
women physiologically capable of becoming pregnant, unless they are using
highly effective methods of contraception during dosing and for 3 month days
after stopping study drug. Highly effective contraception methods include
Total abstinence or
Male or female sterilization or
Combination of any two of the following (a+b or a+c or b+c)
Use of oral, injected or implanted hormonal methods of contraception
Placement of an intrauterine device (IUD) or intrauterine system (IUS)
Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential
[2.1.2.15](telnet://2.1.2.15) Sexually active males must use a condom during
intercourse while taking the drug and for 3 months after stopping study drug
and should not father a child in this period. A condom is required to be used
also by vasectomized men in order to prevent delivery of the drug via seminal
fluid
[2.1.2.16](telnet://2.1.2.16) HIV-positive patients on combination
antiretroviral therapy are ineligible because of the potential for
pharmacokinetic interactions with INC280
[2.1.2.17](telnet://2.1.2.17) Prior invasive malignancy of other histology
currently requiring treatment
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note